MDT 10013

Drug Profile

MDT 10013

Alternative Names: MDT-10013

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Medtronic
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postoperative pain

Most Recent Events

  • 06 Jun 2016 Medtronic withdraws a phase II trial prior to enrolment in Postoperative pain in USA (NCT02263222)
  • 01 Feb 2016 Medtronic completes a phase II trial for Postoperative pain in USA (NCT02077140)
  • 30 Sep 2014 Medtronic plans a phase II trial in Postoperative pain in USA (NCT02263222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top